Drugs / Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides
Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides
also known as
tolDC-VitD3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02903537 | Jul 2017 → Dec 2023 | chronic progressive multiple sclerosis, relapsing-remitting multiple sclerosis | Germans Trias i Pujol Research Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02903537 ↗ |
| Known as | tolDC-VitD3 | “Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)” NCT02903537 ↗ |
| Modality | Cell therapy | “autologous tolerogenic dendritic cells (tolDC) is a promising approach” PMID 31501122 ↗ Sep 2019 |
| Route | Other | “Intranodal administration” NCT02903537 ↗ |